---
title: "AB&B BIO-TECH-B's Huierkangxin® is the only vaccine selected for the preliminary review list of innovative drugs under the national medical insurance"
description: "AB&B BIO-TECH-B announced that its quadrivalent influenza virus subunit vaccine HuiErKangXin® has been included in the preliminary review list of innovative drugs for the national medical insurance. T"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252756369.md"
published_at: "2025-08-13T00:23:03.000Z"
---

# AB&B BIO-TECH-B's Huierkangxin® is the only vaccine selected for the preliminary review list of innovative drugs under the national medical insurance

> AB&B BIO-TECH-B announced that its quadrivalent influenza virus subunit vaccine HuiErKangXin® has been included in the preliminary review list of innovative drugs for the national medical insurance. This vaccine received new drug application approval in May 2023 and is suitable for individuals aged three and above, aiming to provide protection against H1N1, H3N2, and two types of influenza B viruses. The vaccine has undergone significant upgrades based on traditional vaccines, offering advantages such as high purity and low risk of adverse reactions

According to the announcement from the National Healthcare Security Administration on August 12, 2025, Zhonghui Biological-B (02627) announced that the list of innovative drugs for national commercial health insurance that passed the preliminary review this year includes the only vaccine product—the quadrivalent influenza virus subunit vaccine.

The quadrivalent influenza virus subunit vaccine, marketed under the name HuiErKangXin, received approval for its New Drug Application (NDA) from the National Medical Products Administration of China in May 2023. It is intended for use in individuals aged three and older (with a specification of 15μg/0.5ml in terms of the hemagglutinin concentration of the virus strains) and is the first and only quadrivalent influenza virus subunit vaccine approved in China as of July 21, 2025. It aims to provide broad protection against two types of influenza A viruses (H1N1 and H3N2 subtypes) and two types of influenza B viruses (Yamagata and Victoria lineages). This product represents a significant upgrade over traditional virus-inactivated vaccines, offering comprehensive protection, high purity of component antigens, and a low risk of adverse reactions

### Related Stocks

- [02627.HK - AB&B BIO-TECH-B](https://longbridge.com/en/quote/02627.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 彭博新聞報道，康菲石油正在考慮出售其價值 20 億美元的二疊紀資產 | 2 月 20 日（路透社）- 據彭博新聞週五報道，康菲石油正在探索出售其部分二疊紀盆地資產，這是其更廣泛的投資組合精簡的一部分，消息人士透露。這些資產是通過與 Concho Resources 和 Shell（SHEL.L）的交易在多年中收 | [Link](https://longbridge.com/en/news/276478732.md) |
| 沃爾瑪四季度財報超預期但盈利指引不及預期，CEO 稱 “美國低收入家庭只能勉強維持生計” | 沃爾瑪 Q4 營收超預期，新財年盈利指引（每股 2.75-2.85 美元）遠低於市場預期的 2.96 美元，顯示通脹壓力下消費者支出不確定性猶存，拖累股價下跌 1.38%。財報印證 K 型” 分化：高收入家庭驅動增長，低收入羣體 “錢包吃緊 | [Link](https://longbridge.com/en/news/276398633.md) |
| 學習英偉達刺激芯片銷售，AMD 為 “AI 雲” 借款做擔保 | AMD 為擴大市場份額祭出金融 “狠招”！為初創公司 Crusoe 的 3 億美元購芯貸款提供擔保，承諾在其無客户時 “兜底” 租用芯片。這一復刻英偉達 “租卡雲” 路徑的策略雖能短期推高銷量，但也令 AMD 在 AI 需求放緩時面臨更大的 | [Link](https://longbridge.com/en/news/276401504.md) |
| 谷歌突然發佈 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌發佈了最新的大模型 Gemini 3.1 Pro，其推理性能較去年發佈的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 評測中，Gemini 3.1 Pro 得分 77.1%，顯示出強大的推理能力。新模型支持多源數據綜合和複雜 | [Link](https://longbridge.com/en/news/276396515.md) |
| 最高法裁決後特朗普動用替補選擇：加徵 10% 全球關税 | 美國總統特朗普在最高法院裁決後宣佈將加徵 10% 的全球關税，以補救被推翻的關税措施。根據《1974 年貿易法》第 122 條款，現有的關税將全面生效。最高法院裁定特朗普政府的部分關税措施缺乏法律授權。市場風險提示，投資需謹慎。 | [Link](https://longbridge.com/en/news/276477629.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
